Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Show Display Options
Rank Status Study
1 Completed Omega-3 Fatty Acids Supplementation and Atherothrombotic Biomarkers in Type 2 Diabetes and Cardiovascular Disease.
Conditions: Type 2 Diabetes;   Cardiovascular Diseases
Intervention: Dietary Supplement: Omega-3 PUFA
2 Completed
Has Results
Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: Pioglitazone;   Drug: Placebo
3 Completed n-3 Fatty Acid Infusion and Type 2 Diabetes
Condition: Type 2 Diabetes
Intervention: Dietary Supplement: Intralipid +/- Omegaven
4 Enrolling by invitation The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient
Condition: Diabetes Mellitus Type II
Interventions: Dietary Supplement: n-3 Fatty Acid;   Dietary Supplement: Placebo
5 Completed Metabolic Response to 3-day Fast Versus Carbohydrate-free Diet in Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Other: 3 day fast;   Other: 3 day CHO-free diet
6 Recruiting Evaluation of the Effect of Pulsatile Cuts Stendo3 on Vascular Function Patients With Diabetes Type 2
Condition: Type 2 Diabetes
Intervention: Device: Combination pulsatile Stendo3
7 Completed Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo group(once daily);   Drug: LC15-0444 50mg qd
8 Completed Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Dietary Supplement: n-3 PUFAs;   Dietary Supplement: Placebo
9 Completed
Has Results
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine;   Drug: Placebo to match ranolazine;   Drug: Metformin;   Drug: Placebo to match metformin;   Behavioral: Diet;   Behavioral: Exercise
10 Completed Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: GEMIGLIPTIN LS15-0444;   Drug: vildagliptin;   Drug: metformin
11 Completed A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: SYR-472;   Drug: Placebo
12 Active, not recruiting A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: SYR-472 25 mg;   Drug: Placebo + SYR-472 25 mg
13 Completed A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin;   Drug: Placebo
14 Completed Longitudinal Cohort Study Comparing 2 Surgical Techniques in Patients With Class 3 Obesity and Type 2 Diabetes
Conditions: Obesity;   Type 2 Diabetes
Interventions: Procedure: Roux-en-Y gastric bypass;   Procedure: Adjustable gastric band
15 Unknown  Combined Rg3-enriched Korean Red Ginseng and American Ginseng in the Management of Hypertension in Type 2 Diabetes
Conditions: Diabetes Mellitus Type 2;   Hypertension
Interventions: Dietary Supplement: Ginseng;   Dietary Supplement: Wheat Bran
16 Unknown  A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China
Condition: Type 2 Diabetes
17 Unknown  The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics
Condition: Type 2 Diabetes
Interventions: Dietary Supplement: omega-3;   Dietary Supplement: placebo
18 Recruiting The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea
Condition: Maturity-Onset Diabetes of the Young, Type 3
Interventions: Drug: Glimepiride 1Mg Tablet;   Drug: Glucagon-like Peptide-1;   Drug: Glucose-Dependent Insulinotropic Polypeptide;   Drug: Placebo Oral Tablet;   Drug: Placebo infusion
19 Active, not recruiting A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Saxagliptin, Onglyza;   Drug: Dapagliflozin, Farxiga;   Drug: Glargine insulin;   Drug: Metformin XR
20 Active, not recruiting Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes
Condition: Type 2 Diabetes
Interventions: Dietary Supplement: Vitamin D3;   Drug: Omega-3 fatty acid (fish oil);   Dietary Supplement: Vitamin D3 placebo;   Drug: Fish oil placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.